Abstract

Missense mutation is the most common mutation type in hemophilia. However, the majority of missense mutations remain uncharacterized. Here we characterize how hemophilia mutations near the unused N-glycosylation site of the A2 domain (N582) of FVIII affect protein conformation and intracellular trafficking. N582 is located in the middle of a short 310-helical turn (D580-S584), in which most amino acids have multiple hemophilia mutations. All 14 missense mutations found in this 310-helix reduced secretion levels of the A2 domain and full-length FVIII. Secreted mutants have decreased activities relative to WT FVIII. Selected mutations also lead to partial glycosylation of N582, suggesting that rapid folding of local conformation prevents glycosylation of this site in wild-type FVIII. Protease sensitivity, stability and degradation of the A2 domain vary among mutants, and between non-glycosylated and glycosylated species of the same mutant. Most of the mutants interact with the ER chaperone BiP, while only mutants with aberrant glycosylation interact with calreticulin. Our results show that the short 310-helix from D580 to S584 is critical for proper biogenesis of the A2 domain and FVIII, and reveal a range of molecular mechanisms by which FVIII missense mutations lead to moderate to severe hemophilia A.

Highlights

  • Hemophilia A is an X-linked recessive bleeding disorder caused by a quantitative or qualitative deficiency of coagulation factor VIII (FVIII)

  • N-linked glycosylation sequences in FVIII outside of the B domain are located in the A1 domain (N41, N239), the A2 domain (N582), the A3 domain (N1810) and the C1 domain (N2118)

  • Twelve hours after tunicamycin treatment, COS-1 and HEK293T cells transfected with individual FVIII domain plasmids were harvested and the sizes of FVIII domains were analyzed by anti-Flag immunoblotting

Read more

Summary

Introduction

Hemophilia A is an X-linked recessive bleeding disorder caused by a quantitative or qualitative deficiency of coagulation factor VIII (FVIII). FVIII is a cofactor for factor IXa (FIXa) that accelerates the activation of factor X, playing an essential role in the intrinsic pathway of the coagulation cascade[1] Based on their plasma FVIII levels, hemophilia A patients are classified as mild (0.05–0.4 U/ml), moderate (0.01–0.05 U/ml) or severe (

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call